Compare Agilent Technologies Inc (A) vs InMode Ltd (INMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs InMode Ltd — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while InMode Ltd trades at $14.46 (market cap $835.77M). The key difference: Agilent Technologies Inc is far larger — about 44.3× InMode Ltd's market cap, and Agilent Technologies Inc pays a 0.78% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| A | INMD | |
|---|---|---|
Market Cap | $37.04B | $835.77M |
Sector | Health | Technology |
52-Week High | $157.20 | $16.62 |
52-Week Low | $110.24 | $12.76 |
Enterprise Value | $38.59B | $303.44M |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
INMD trades at $14.60, down 1.35% on the day, with mixed technical signals showing bullish moving averages but neutral oscillators. The company maintains strong profitability with 77.84% gross margins and 23.27% net income margins, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited buyout proposal at $16.20 per share and multiple securities fraud investigations announced in early July 2026.
The stock appears undervalued with a P/E of 10.81 and EV/EBITDA of 3.81, but faces near-term headwinds from legal investigations and earnings volatility. Analyst consensus sits at Hold with a $16.50 price target, representing 13% upside potential from current levels, though the ongoing legal scrutiny creates uncertainty for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
